...
首页> 外文期刊>Trials >Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial
【24h】

Remote ischemic preconditioning in the prevention of ischemic brain damage during intracranial aneurysm treatment (RIPAT): study protocol for a randomized controlled trial

机译:远程缺血预处理预防颅内动脉瘤治疗(RIPAT)期间的缺血性脑损伤:一项随机对照试验的研究方案

获取原文

摘要

Background The treatment of intracranial aneurysms may be associated with cerebral ischemia. We hypothesize that pre-interventional remote ischemic preconditioning (RIPC) reduces ischemic cerebral tissue damage in patients undergoing elective intracranial aneurysm treatment. Methods/Design This study is a single-center, prospective, randomized, double-blind explorative trial. Patients with an unruptured intracranial aneurysm admitted to Innsbruck Medical University Hospital for coiling or clipping will be consecutively randomized to either the intervention group (= RIPC by inflating an upper extremity blood-pressure cuff for 3 x 5?min to 200?mmHg) or the control group after induction of anesthesia. Participants will be randomized 1:1 to either the preconditioning group or the sham group using a random allocation sequence and block randomization. The precalculated sample size is n =?24 per group. The primary endpoint is the area-under-the-curve concentration of serum biomarkers (S100B, NSE, GFAP, MMP9, MBP, and cellular microparticles) in the first five days after treatment. Secondary endpoints are the number and volume of new ischemic lesions in magnetic resonance imaging and clinical outcome evaluated with the National Institutes of Health Stroke Scale, the modified Rankin Scale, and neuropsychological tests at six and twelve months. All outcome variables will be determined by observers blinded to group allocation. This study was approved by the local institutional Ethics Committee (UN5164), version 3.0 of the study protocol, dated 20 October 2013. Discussion This study uses the elective treatment of intracranial aneurysms as a paradigmatic situation to explore the neuroprotective effects of RIPC. If effects are demonstrable in this pilot trial, a larger, prospective phase III trial will be considered.
机译:背景颅内动脉瘤的治疗可能与脑缺血有关。我们假设,介入性远程缺血预处理(RIPC)减少了接受择期颅内动脉瘤治疗的患者的缺血性脑组织损伤。方法/设计本研究是一项单中心,前瞻性,随机,双盲探索性试验。因斯布鲁克医科大学医院(Innsbruck Medical University Hospital)因盘绕或夹伤而入院的颅内动脉瘤未破裂的患者,将被连续随机分为干预组(RIPC,将上肢血压袖带充气3 x 5?min至200?mmHg)或对照组在诱导麻醉后。使用随机分配序列和区组随机化将参与者以1:1的比例分配到预处理组或假组。预先计算的样本量为每组n =?24。主要终点是治疗后前五天血清生物标志物(S100B,NSE,GFAP,MMP9,MBP和细胞微粒)的曲线下面积浓度。次要终点是在6到12个月使用国立卫生研究院卒中量表,改良的兰金量表和神经心理学测试评估的磁共振成像中新的缺血性病变的数量和体积以及临床结果。所有结果变量将由不知道分组的观察员确定。这项研究已获当地机构伦理委员会(UN5164)批准,研究方案的3.0版,日期为2013年10月20日。讨论这项研究以颅内动脉瘤的选择性治疗为例,探讨了RIPC的神经保护作用。如果在该试验中可以证明效果,将考虑进行更大的前瞻性III期试验。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号